Inhibikase Therapeutics, Inc. - Common Stock, $0.001 par value (IKT)

CUSIP: 45719W205

Q1 2024 13F Holders as of 31 Mar 2024

Type / Class
Equity / Common Stock, $0.001 par value
Shares outstanding
128,205,929
Total 13F shares
205,558
Share change
-29,446
Total reported value
$443,782
Price per share
$2.16
Number of holders
12
Value change
-$62,190
Number of buys
5
Number of sells
6

Quarterly Holders Quick Answers

What is CUSIP 45719W205?
CUSIP 45719W205 identifies IKT - Inhibikase Therapeutics, Inc. - Common Stock, $0.001 par value in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of Inhibikase Therapeutics, Inc. - Common Stock, $0.001 par value (IKT) as of Q1 2024

As of 31 Mar 2024, Inhibikase Therapeutics, Inc. - Common Stock, $0.001 par value (IKT) was held by 12 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 205,558 shares. The largest 10 holders included BLAIR WILLIAM & CO/IL, GEODE CAPITAL MANAGEMENT, LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, RENAISSANCE TECHNOLOGIES LLC, Redmond Asset Management, LLC, VANGUARD GROUP INC, STATE STREET CORP, UBS Group AG, Tower Research Capital LLC (TRC), and OSAIC HOLDINGS, INC.. This page lists 12 institutional shareholders reporting positions in this security for the Q1 2024 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.